Vindesine-Mitoxantrone (VM) Versus Vindesine-4′-Epidoxorubicin (VE) in Metastatic Breast Cancer: A Prospective Randomized Trial
H. Hausmaninger(Unfallkrankenhaus Salzburg), M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 0
Related Papers
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
|PubMed|1996|388
Clinical multidrug resistance in cancer: A multifactorial problem
|European Journal of Cancer|1996|178